Table 2.
Adjusted risk of malignancy associated with antidiabetic medications, use vs. non-use
| Antidiabetic medication | ORa
(95 % CI) |
P value | ORb
(95 % CI) |
P value | ORc
(95 % CI) |
P value |
|---|---|---|---|---|---|---|
| Metformin |
0.294
(0.182–0.478) |
<0.001 |
0.318
(0.193–0.523) |
<0.001 |
0.310
(0.183–0.525) |
<0.001 |
| Sulfonylurea | 0.735 (0.493–1.094) |
0.129 | 0.859 (0.547–1.349) |
0.508 | 0.906 (0.563–1.456) |
0.683 |
| Acarbose | 1.333 (0.640–2.776) |
0.443 | 1.372 (0.635–2.967) |
0.421 | 1.245 (0.564–2.747) |
0.587 |
| DPP-4 inhibitors | 1.954 (0.698–5.468) |
0.202 | 2.809 (0.947–8.331) |
0.063 |
3.468
(1.082–11.112) |
0.036 |
| Insulin |
1.964
(1.227–3.144) |
0.005 | 1.509 (0.879–2.588) |
0.135 | 1.735 (0.986–3.053) |
0.056 |
a adjusted for BMI, diabetes duration and metabolic control
b adjusted for BMI, diabetes duration, metabolic control and antidiabetic medications use
c adjusted for BMI, diabetes duration, metabolic control, antidiabetic medications use, smoking history, place of residence, presence of comorbidities and aspirin use
Data presented in bold are statistically significant